Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation

Liang-He Lu1,2,3 | Jie Mei1,2,3 | Anna Kan1,2,3 | Yi-Hong Ling2,3,4 | Shao-Hua Li1,2,3 | Wei Wei1,2,3 | Min-Shan Chen1,2,3 | Yong-Fa Zhang5,6 | Rong-Ping Guo1,2,3

1Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
2State Key Laboratory of Oncology in South China, Guangzhou, China
3Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
4Department of Pathology, Sun Yat-sen University Cancer Center, Shanghai, China
5Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
6Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

Correspondence
Rong-Ping Guo, Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Email: guorp@sysucc.org.cn
Yong-Fa Zhang, Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200433, China.
Email: sysucczyf@163.com

Funding information
Clinical Trials Project (5010 Project) of Sun Yat-sen University, Grant/Award Number: 5010-2017009; Clinical Trials Project (308 Project) of Sun Yat-sen University Cancer Center, Grant/Award Number: 308-2015-014; National Natural Science Foundation of China, Grant/Award Number: 81871985; Natural Science Foundation of Guangdong Province, Grant/Award Number: 2017A030310203

Abstract
Background and aims: The optimal treatment strategy for recurrent hepatocellular carcinoma (HCC) remains unclear. Therefore, we aimed to compare the outcomes of repeat hepatic resection (RHR) and radiofrequency ablation (RFA) for recurrent HCC.

Method: From December 2004 to December 2015, 138 patients who underwent RHR and 194 patients who underwent RFA were enrolled. Propensity score matching (PSM) was performed to establish 1:1 RHR-RFA group matching. Clinical outcomes were compared before and after matching.

Results: Before matching, the 1-, 3-, and 5-year postrecurrence survival (PRS) rates were 91.8%, 82.0%, and 72.9% for the RHR group (n = 138) and 94.4%, 75.4%, and 61.7% for the RFA group (n = 194), respectively (P = .380). After matching, the PRS rates at 1, 3, and 5 years were 90.5%, 81.5%, and 71.8% for the RHR group (n = 120) and 91.0%, 61.0%, and 41.7% for the RFA group (n = 120), respectively (P = .002). In the subgroup analysis, the PRS rates for the RHR group were better than those for the RFA group for patients who relapsed within 2 years (P = .004) or patients with primary tumor burden beyond the Milan criteria (P = .004). Multivariate analysis showed that treatment allocation was identified as an independent prognostic factor for PRS.

Conclusion: Compared with RFA, RHR provided a survival advantage for recurrent HCC, especially for patients who relapsed within 2 years and those with primary tumor burden beyond the Milan criteria.

Keywords
postrecurrence survival, radiofrequency ablation, recurrent hepatocellular carcinoma, repeat hepatic resection
1 | INTRODUCTION

Hepatocellular carcinoma (HCC) is among the most common cancers and is the leading cause of cancer-related mortality worldwide.\(^1\) Although hepatic resection is commonly chosen as a curative treatment for HCC, long-term outcomes after hepatic resection are not yet satisfactory, as tumor recurrence within the liver occurs in up to 60%-80% within 5 years.\(^2-4\) Moreover, guidelines for the management of recurrent HCC remain controversial and poorly defined.

Intrahepatic recurrence is the main cause of postoperative death for HCC in clinical practice, and the postrecurrence survival (PRS) of HCC patients is greatly impacted by the characteristics of the recurrent tumor and the corresponding treatment modalities.\(^5-7\) Currently, the available treatment options for recurrent HCC are not particularly different from those for primary HCC. Repeat hepatic resection (RHR) continues to be the conventional option for recurrent HCC with preserved liver function and residual liver volume,\(^8-11\) and advances in surgical techniques and perioperative care have resulted in improved safety in RHR. In addition, as a minimally invasive option, radiofrequency ablation (RFA) has emerged as another alternative treatment modality for small HCC.\(^12\) Several studies have previously recommended RHR when possible in the treatment of recurrent HCC.\(^9-11\) However, conflicting data have also shown that outcomes following RFA are similar to those following RHR for the management of recurrent HCC.\(^13-16\) Thus, the outcomes of RHR and RFA for the treatment of recurrent HCC remain unclear and controversial.

In this study, we compared the outcomes of recurrent HCC treated by RHR or RFA using a large cohort. Propensity score matching (PSM) analysis was carried out to minimize the bias that arises from different patient backgrounds.

2 | MATERIALS AND METHODS

2.1 | Patients

From December 2004 to December 2015, a total of 1186 HCC patients developed recurrence after initial resection. Among these patients, 144 (12.1%) were amenable to RHR, 203 (17.1%) received RFA, 678 (57.2%) underwent chemoembolization, 76 (6.4%) received sorafenib, and 85 (7.2%) received only supportive treatment. Recurrent HCC was defined as the appearance of a new lesion with radiologic features typical of HCC, as confirmed by two or more imaging modalities. The following criteria were used for patient selection: (a) age between 18 and 75 years; (b) a diagnosis of intrahepatic recurrent HCC after initial curative hepatic resection; (c) no radiologic evidence of macroscopic vascular invasion or extrahepatic metastasis; (d) RHR or RFA performed as the initial treatment for recurrent HCC; and (e) Child-Pugh class A or B. Thus, six patients in the RHR cohort were excluded, including four patients who received palliative repeated resection and two patients with other malignancies. Nine patients in the RFA cohort were excluded, including five patients older than 75 years and four patients with extraneoplastic metastasis. In total, 342 consecutive patients who underwent RHR (n = 138) or RFA (n = 194) were ultimately enrolled. The correction of potential confounding factors that may affect the outcome of these groups was performed with 1:1 PSM. Finally, 120 patients who underwent RHR and 120 patients who underwent RFA as the first treatment for recurrent HCC were enrolled. This study was approved by the Institutional Review Board of our center and conducted according to the ethical guidelines of the 1975 Declaration of Helsinki.

2.2 | Treatment strategy

Treatment selection for recurrent HCC was decided by our multidisciplinary team. RHR was assigned when there was the possibility for the complete removal of all tumors while retaining a sufficient liver remnant with an expected remnant liver volume of no less than 250 ml/m\(^2\), as assessed by our multidisciplinary team. Resection was avoided if patients had gross ascites, severe portal hypertension, or inadequate liver remnant. Reasons for assigning RFA instead of RHR included psychological resistance to invasive treatment, refusal of general anesthesia, and an insufficient liver remnant.

2.3 | RHR procedure

Repeat hepatic resection was performed using previously described techniques.\(^17\) Intraoperative ultrasound was routinely performed to assess the tumor burden, the liver remnant, and the possibility of a negative resection margin. Pringle's maneuver, with a clamp/unclamp time of 10 min/5 min, was performed if necessary. Anatomic resection was our preferred surgical method. If the liver remnant was inadequate, nonanatomic resection was performed with a negative resection margin.

2.4 | RFA procedure

Radiofrequency ablation was performed with the use of conscious analgesic sedation and local anesthesia. All procedures were performed percutaneously under real-time ultrasound guidance.\(^18,19\) A Cool-tip RFA system (Radionics) with a 3 cm active tip length was used for ablation. The numbers of overlapping ablations and ablation points were determined
by the number and diameter of the tumor with the aim of achieving an ablative margin of at least 0.5 cm in the normal tissue surrounding the tumor. At the end of the procedure, the needle tract was ablated to prevent bleeding and tumor seeding.

### 2.5 Follow-up

In both groups, dynamic enhanced computed tomography (CT) was conducted 4 weeks after the treatment to evaluate the efficacy of the technique. Thereafter, the patients were followed up once every 3 months for the first 2 years and then once every 6 months after 2 years. At each follow-up session, blood tests, including serum liver function tests and AFP tests, as well as abdominal contrast material-enhanced three-phase dynamic spiral CT or magnetic resonance imaging, if necessary, were carried out. All patients with hepatitis-related HCC who were prepared for the initial resection of their HCC in our hospital were counseled by a hepatologist for antiviral therapy regardless of the serum HBV DNA result.\(^{20,21}\)

### 2.6 Statistical analysis

The main end point of this study was PRS, which was defined as the date of recurrence until death or the end of the follow-up period. PSM was performed to reduce the patient selection bias and confounding variables between the RHR and RFA groups according to age, tumor size at recurrence, tumor number at recurrence, and Child-Pugh score. A one-to-one nearest neighbor matching algorithm was performed with a caliper of 0.1. Comparisons of the RHR and RFA groups were performed using \( t \) tests for continuous variables and chi-square or Fisher's exact tests for categorical variables before and after PSM. The PRS curves were calculated by the Kaplan-Meier method and analyzed with a log-rank test. All variables that yielded a \( P \) value of <.05 in the univariate analysis were subjected to a multivariate analysis using Cox proportional hazards models. All tests were two-sided, and a significant difference was considered when \( P < .05 \). Statistical analysis was performed using SPSS 24.0 (SPSS Inc).

### 3 RESULTS

The baseline characteristics before and after PSM are summarized in Tables 1 and 2. Before matching, the median follow-up period after recurrence was 37.6 months for the RHR group and 41.6 months for the RFA group. Compared with those in the RHR group, patients in the RFA group were older (52.9 ± 11.8 years vs 50.1 ± 10.9 years, \( P = .028 \)), more patients relapsed within 2 years after initial hepatic resection (65.5% vs 39.1%, \( P < .001 \)), and exhibited smaller recurrent tumor sizes (1.9 ± 0.9 cm vs 2.8 ± 1.9 cm, \( P < .001 \)). After matching, there was no significant difference between the RHR and RFA groups (Tables 1 and 2). For patients with recurrent HCC who received RHR or RFA, repeated recurrence was observed in 128 patients, including 69 of 120 (57.5%) in the RFA cohort and 59 of 120 (49.2%) patients in the RHR cohort. Among the 128 patients with repeated recurrence, 52 of 69 (75.4%) patients in the RFA cohort and 31 of 59 (52.5%) patients in the RHR cohort developed only intrahepatic recurrence.

### 3.1 Postrecurrence survival

Before matching, a total of 78 patients died from recurrent HCC, including 52 of the 194 (26.8%) patients in the RFA cohort and 26 of the 138 (18.8%) patients in the RHR cohort. For the RHR group, the 1-, 3-, and 5-year PRS rates were 91.8%, 82.0%, and 72.9%, respectively. In contrast, for the RFA group, the 1-, 3-, and 5-year PRS rates were 94.4%, 75.4%, and 61.7%, respectively (\( P = .380 \)) (Figure 1A). After matching, a total of 76 patients died from recurrent HCC, including 52 of 120 (43.3%) patients in the RFA cohort and 24 of 120 (20.0%) patients in the RHR cohort. For the RHR group, the 1-, 3-, and 5-year PRS rates were 90.5%, 81.5%, and 71.8%, respectively. For the RFA group, the respective 1-, 3-, and 5-year PRS rates were 91.0%, 61.0%, and 41.7%, respectively (\( P = .002 \)) (Figure 1B).

### 3.2 Subgroup analysis of PRS

For 47 patients in the RHR group and 62 patients in the RFA group who presented tumor recurrence within 2 years after the initial hepatic resection, the respective 1-, 3-, and 5-year PRS rates were 83.5%, 69.7%, and 65.4% for the RHR group and 84.8%, 45.9%, and 22.7%, respectively, for the RFA group (\( P = .004 \)) (Figure 2A). For patients with an interval of tumor recurrence >2 years, there was no significant difference in the PRS rates between patients treated by RHR or RFA (\( P = .718 \)) (Figure 2B).

For 45 patients in the RHR group and 54 patients in the RFA group who had an initial tumor burden beyond the Milan criteria, the respective 1-, 3-, and 5-year PRS rates were 90.4%, 84.5%, and 64% in the RHR group and 88.2%, 53.6%, and 29.8%, respectively, in the RFA group (\( P = .004 \)) (Figure 2D). There was no significant difference in PRS rates between patients with an initial tumor burden within the Milan criteria (\( P = .237 \)) (Figure 2C).
With regard to PRS, age > 55 years (hazard ratio [HR]: 1.60, 95% confidence interval [CI]: 1.00-2.53, \( P = .048 \)), the presence of hepatitis (HR: 2.78, 95% CI: 1.41-5.36, \( P = .003 \)), time to recurrence >2 years (HR: 0.31, 95% CI: 0.19-0.51, \( P < .001 \)), serum AFP level at recurrence >20 ng/mL (HR: 1.79, 95% CI: 1.13-2.84, \( P = .013 \)), and treatment allocation (HR: 0.54, 95% CI: 0.33-0.88, \( P = .014 \)) were evaluated as significant factors (Table 3).

### Table 3: Patient characteristics at the time of recurrence before and after PSM

| Variables                        | Before matching | After matching |
|----------------------------------|-----------------|---------------|
|                                  | RFA (n = 194)   | RHR (n = 138) | \( P \)  |
|                                  | RFA (n = 120)   | RHR (n = 120) | \( P \)  |
| Age, y                           | 52.9 ± 11.8     | 50.1 ± 10.9   | .028 |
| Male sex                         | 172 (88.7)      | 124 (89.9)    | .730 |
|                                  | 104 (86.7)      | 108 (90.0)    | .421 |
| Hepatitis                        |                |               |       |
| HBV                              | 172 (88.7)      | 126 (91.3)    | .725 |
| HCV                              | 6 (3.1)         | 3 (2.2)       | .725 |
| Others                           | 16 (8.2)        | 9 (6.5)       | .725 |
| WBC, 10^9/L                      | 6.4 ± 1.8       | 6.4 ± 1.8     | .773 |
| PLT, 10^9/L                      | 166.0 ± 57.3    | 176.0 ± 64.8  | .138 |
| ALT, U/L                         | 55.0 ± 87.4     | 54.1 ± 137.8  | .942 |
| ALB, g/L                         | 41.8 ± 6.4      | 42.5 ± 3.6    | .176 |
| TBIL, μmol/L                     | 15.3 ± 8.9      | 14.9 ± 5.8    | .666 |
| AFP at recurrence, ng/mL         |                |               |       |
| >20                              | 71 (36.6)       | 43 (31.2)     | .304 |
| ≤20                              | 123 (63.4)      | 95 (68.8)     | .304 |
| Child-Pugh score at recurrence   |                |               |       |
| 5                                | 184 (94.8)      | 136 (98.6)    | .138 |
| 6                                | 10 (5.2)        | 2 (1.4)       | .138 |
| Cirrhosis                        | 134 (69.1)      | 96 (69.6)     | .924 |
| Time to recurrence               |                |               |       |
| >2 y                             | 67 (34.5)       | 84 (60.9)     | <.001 |
| ≤2 y                             | 127 (65.5)      | 54 (39.1)     | <.001 |
| Tumor size at recurrence, cm     | 1.9 ± 0.9       | 2.8 ± 1.9     | <.001 |
| Solitary                         | 162 (83.5)      | 112 (81.2)    | .579 |
| Multiple                         | 32 (16.5)       | 26 (18.8)     | .579 |
| Tumor number at recurrence       |                |               |       |

Note: Variables are expressed as the mean ± SD or n (%).
Abbreviations: AFP, α-fetoprotein; ALB, albumin; ALT, alanine aminotransferase; PLT, platelet; PSM, propensity score matching; RFA, radiofrequency ablation; RHR, repeat hepatic resection; TBIL, total bilirubin; WBC, white blood cell.

### 3.3 | Univariate and multivariate analyses of PRS

With regard to PRS, age > 55 years (hazard ratio [HR]: 1.60, 95% confidence interval [CI]: 1.00-2.53, \( P = .048 \)), the presence of hepatitis (HR: 2.78, 95% CI: 1.41-5.26, \( P = .003 \)), time to recurrence >2 years (HR: 0.31, 95% CI: 0.19-0.51, \( P < .001 \)), serum AFP level at recurrence >20 ng/mL (HR: 1.79, 95% CI: 1.13-2.84, \( P = .013 \)), and treatment allocation (HR: 0.54, 95% CI: 0.33-0.88, \( P = .014 \)) were evaluated as significant factors (Table 3).

### 3.4 | Treatment complications

Treatment-related complications are summarized in Table 4. Complications were reported according to the Clavien-Dindo grade. Major complications were those classified as Clavien-Dindo grade III or higher. No treatment-related mortality was reported in this study, and the incidence of major complications did not differ significantly between the RHR and RFA groups (Table 4).
This study demonstrated that RHR was more effective than RFA for extending the postoperative recurrence survival time in HCC patients after the initial recurrence, especially for patients who relapsed within 2 years or those who had an initial tumor burden beyond the Milan criteria.

The Barcelona clinic liver cancer (BCLC) staging system was initially established as a link between staging and treatment indications for primary HCC. For naïve HCC
It is generally accepted that the survival outcome of RFA is comparable to hepatic resection for small HCC. However, the treatment of recurrent HCC does not strictly follow the BCLC staging system, as expected differences should be considered when determining treatment options for recurrent tumors. First, the size of the recurrent tumor may be smaller than the initial tumor due to more frequent surveillance. Because all patients enrolled in this study were diagnosed with intrahepatic recurrent HCC after the initial curative hepatic resection, the finding that the median tumor size of the primary HCC summarized in the table was >5 cm is reliable, since RFA may be inferior for local tumor control. However, due to more frequent surveillance after initial resection, the median size of recurrent HCC in both cohorts in this study was mostly <3 cm, with no significant difference observed, as summarized in Figure 1 and Figure 2.
in Table 1 (RHR vs RFA: 2.4 ± 1.1 cm vs 2.2 ± 1.0 cm, \( P = .091 \)). In addition, the limitations in liver function reserve cannot be ignored after the initial resection. Several studies reported generally comparable outcomes between RHR and RFA, although a tendency toward longer survival time was observed in the RHR group than in the RFA group. Conversely, others have argued that RHR should be considered the most effective treatment for intrahepatic recurrence HCC. In summary, the study limitations, including the small sample size and short follow-up period, may have led to our failure to identify an association between PRS and risk factors.

In addition to the type of treatment, our study identified the presence of hepatitis and serum AFP level at recurrence as independent factors associated with PRS in the multivariate analysis. Among patients who relapse within 2 years or who have an initial tumor burden beyond the Milan criteria, RHR provided a survival advantage for recurrent HCC compared with RFA. As HCC is more likely to microdisseminate into the tributaries of the portal branches and shed tumor
emboli into the neighboring branches of the same liver segment, RHR may offer a better chance to eradicate intrahepatic micrometastases generated from the original tumor than RFA. Another explanation may be that RFA was reported to be inferior to surgery for local tumor control. Relapse beyond 2 years after initial resection is now generally believed to be due to multicentric carcinogenesis because of hepatitis or cirrhosis, and our study showed that there was no significant difference in the long-term outcomes of patients who received RHR or RFA, consistent with previous studies.

In fact, the rate of repeated resection in clinical practice was less than 30%. In addition to the limited liver remnant, another possible obstacle to RHR may be the assumption that RHR is more difficult to perform due to postoperative adhesion and anatomic changes. However, a systematic review reported that the 5-year patient survival rate after recurrence who underwent repeated liver resection ranged from 22.0% to 84.0%, and the data of Yoh et al showed that the 5-year survival rate after recurrence was 73.8% for HCC patients with intrahepatic recurrence who underwent repeat resection, which was consistent with our results. Thus, the results of our study indicated that RHR should not be ignored but performed carefully when surgical resection is considered feasible in clinical practice. Although RFA is generally regarded as safer and less invasive than RHR, both treatment groups suffered similar treatment complication morbidity rates. This may be related to the introduction of PSM and the improvement in the perioperative management of modern surgery.

The limitations of this study should also be noted. First, deviation may be unavoidable due to the retrospective design of our study. Second, treatment selection for recurrent HCC was decided by our multidisciplinary team and not randomly assigned. For HCC patients who had major resection, when recurrence was present and located deep within the liver or in a patient with insufficient liver function reserve, RHR should be carefully considered to determine whether it would offer any benefit to the patient. Thus, a prospective, randomized trial is needed to compare the efficacy of RHR and RFA for the treatment of recurrent HCC.

In conclusion, the results of our study showed that RHR is relatively safe and yielded better PRS rates than RFA for recurrent HCC, especially in patients who relapse within 2 years or who have a primary tumor burden beyond the Milan criteria.

ACKNOWLEDGMENTS
This study was supported by grants from the Clinical Trials Project (5010 Project) of Sun Yat-sen University (no. 5010-2017009), the Clinical Trials Project (308 Project) of Sun Yat-sen University Cancer Center (no. 308-2015-014), the National Natural Science Foundation of China (no. 81871985), and the Natural Science Foundation of Guangdong Province (no. 2017A030310203).

AUTHOR CONTRIBUTIONS
Liang-He Lu: Conceptualization, project administration, formal analysis, software, and writing—review and editing. Jie Mei: Conceptualization, formal analysis, software, and writing—original draft. Anna Kan: Data curation, formal analysis, methodology. Shao-Hua Li: Data curation, formal analysis, funding acquisition. Wei Wei: Data curation, formal analysis, funding acquisition. Mu-Yan Cai: Data curation, formal analysis, resource. Min-Shan Chen: Data curation, project administration, resources. Yong-Fa Zhang: Conceptualization, software, writing—original draft. Rong-Ping Guo: Conceptualization, supervision, writing—review and editing.

DATA AVAILABILITY STATEMENT
Key raw data of this study have been uploaded onto the Research Data Deposit public platform (www.researchdata.org.cn) (no. RDDA2019001076).

ORCID
Rong-Ping Guo https://orcid.org/0000-0003-2799-3463

REFERENCES
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
2. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301-1314.
3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524.
4. Tabrizian P, Jibara G, Shraga B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. *Ann Surg*. 2015;261:947-955.

5. Chen W-T, Chau G-Y, Lui W-Y, et al. Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. *Eur J Surg Oncol*. 2004;30:414-420.

6. Kishi Y, Saito A, Yamamoto J, et al. Repeat treatment for recurrent hepatocellular carcinoma: is it validated? *Langenbecks Arch Surg*. 2011;396:1093-1100.

7. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. *Ann Surg*. 1999;229:216-222.

8. Matsuda Y, Ito T, Oguchi Y, Nakajima K, Izukura T. Rationale of surgical management for recurrent hepatocellular carcinoma. *Ann Surg*. 1993;217:28-34.

9. Itamoto T, Nakahara H, Amano H, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma. *Surgery*. 2007;141:589-597.

10. Zhou Y, Sui C, Li B, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma: a local experience and a systematic review. *World J Surg Oncol*. 2010;8:55.

11. Sugimachi K, Maehara S, Tanaka S, Shimada M, Sugimachi K. Repeat hepatectomy is the most useful treatment for recurrent hepatocellular carcinoma. *J Hepatobiliary Pancreat Surg*. 2001;8:410-416.

12. Bruix J, Sherman M; American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. *Hepatology*. 2011;53:1020-1022.

13. Song KD, Lim HK, Rhim H, et al. Repeated hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma after hepatic resection: a propensity score matching study. *Radiology*. 2015;275:599-608.

14. Liang H-H, Chen M-S, Peng Z-W, et al. Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: a retrospective study. *Ann Surg Oncol*. 2008;15:3484-3493.

15. Eisele RM, Chopra SS, Lock JF, Glanemann M. Treatment of recurrent hepatocellular carcinoma confined to the liver with repeated resection and radiofrequency ablation: a single center experience. *Technol Health Care*. 2013;21:9-18.

16. Chan ACY, Poon RTP, Cheung TT, et al. Survival analysis of re-resection versus radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. *World J Surg*. 2012;36:151-156.

17. Lu L-H, Zhang Y-F, Mu-Yan C, et al. Platelet-albumin-bilirubin grade: risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. *Digest Liver Dis*. 2019;51(10):1430-1437.

18. Peng Z-W, Zhang Y-J, Chen M-S, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. *J Clin Oncol*. 2013;31:426-432.

19. Chen M-S, Li J-Q, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. *Ann Surg*. 2006;243:321-328.

20. Wong JS, Wong GL, Tsai KK, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. *Aliment Pharmacol Ther*. 2011;33:1104-1112.

21. Nakano M, Koga H, Ide T, et al. Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: a prospective multicenter cohort study. *Cancer Med*. 2019;8:2646-2653.

22. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg*. 2009;250:187-196.

23. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis*. 1999;19:329-338.

24. Huang J, Yan L, Zheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. *Ann Surg*. 2010;252:903-912.

25. Peng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. *J Hepatol*. 2012;57:794-802.

26. Doyle A, Gorgen A, Muaddi H, et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. *J Hepatol*. 2019;70:866-873.

27. Sasaki A, Kai S, Iwashita Y, Hirano S, Ohta M, Kitano S. Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. *Cancer*. 2005;103:299-306.

28. Poon RT. Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. *Ann Surg Oncol*. 2009;16:792-794.

29. Du ZG, Wei YG, Chen KF, Li B. Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution's experience with 398 consecutive patients. *Hepatobiliary Pancreat Dis Int*. 2014;13:153-161.

30. Kim G-A, Shim JH, Kim M-J, et al. Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas. *Br J Surg*. 2016;103:126-135.

31. Peng ZW, Liu FR, Ye S, et al. Radiofrequency ablation versus open hepatic resection for elderly patients (> 65 years) with very early or early hepatocellular carcinoma. *Cancer*. 2013;119:3812-3820.

32. Hung H, Chiu Y, Hsia C, et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. *Clin Gastroenterol Hepatol*. 2011;9:79-86.

33. Minagawa M, Makuchii M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. *Ann Surg Oncol*. 2003;20:703-710.

34. Erridge S, Pucher PH, Markar SR, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. *Br J Surg*. 2017;104:1433-1442.

35. Yoh T, Seo S, Taura K, et al. Surgery for recurrent hepatocellular carcinoma: achieving long-term survival. *Ann Surg*. 2019.

How to cite this article: Lu L-H, Mei J, Kan A, et al. Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation. *Cancer Med*. 2020;9:2997–3005. https://doi.org/10.1002/cam4.2951